Although systemic antibiotics are likely to AZD2281 mouse remain the primary treatment option for patients
with moderate-to-severe COPD, inhaled antibiotics may provide a more appropriate way for the treatment and prevention of exacerbations in the future, particularly for the frequent exacerbators with chronic bacterial infection and for those with radiologically confirmed bronchiectasis. Regardless of the route of administration, however, further studies are required to estimate the potential risks of antibiotic prophylaxis in terms of long-term adverse events and resistance development and to assess whether benefit outweighs the potential risks. Antonio Anzueto has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies including: AstraZeneca, Boehringer Ingelheim, Bayer, Pfizer, GlaxoSmithKline, Sanofi-Aventis. A. Anzueto has been a consultant for AstraZeneca, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Sanofi-Aventis, Bayer. He has also been the principal investigator for research grants for the University of Texas Health Science Center (San Antonio, TX, USA) and was paid for participating in a multicentre clinical trial sponsored by: GlaxoSmithKline, Navitoclax clinical trial Bayer, Lilly
and National Institutes of Health. Marc Miravitlles has received speaker fees from Boehringer Ingelheim, Pfizer, AstraZeneca, Bayer Schering, Novartis, Talecris-Grifols, Carnitine dehydrogenase Takeda-Nycomed, Merck, Sharp & Dohme and Novartis, and consulting fees from Boehringer Ingelheim, Pfizer, GSK, AstraZeneca, Bayer Schering, Novartis, Almirall, Merck, Sharp & Dohme, Talecris-Grifols and Takeda-Nycomed. Sanjay Sethi has received institutional research funds from AstraZeneca and GlaxoSmithKline. He has received lecture and/or consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Forest, Pfizer, GlaxoSmithKline, Mpex, and Novartis. Robert Wilson has received honoraria for taking part in advisory boards and presenting at meetings from Almirall, Aperion Advisors LLC, AstraZeneca, Athena Medical PR, Bayer HealthCare, Forest Laboratories (Bronchiectasis
symposium), Genactis Ltd, Opticom International, Penn Technology Partnership, Resolutions Group, Rivervest, Transave, VacZine Analytics and Wyeth Pharmaceuticals. Highfield Communication, Oxford, UK, provided editorial assistance in the preparation of this manuscript. “
“Tuberculosis (TB) is one of the most common global infectious diseases with high mortality.1 For preventing further TB transmission, control should focus on early diagnosis and treatment of latent TB infection (LTBI).2 Next to TB contacts, the dialysis population, growing as a consequence of global ageing, is a known risk group due to attenuated immunity.3, 4 and 5 Defined by interferon-gamma release assays (IGRAs), LTBI has been associated with a decline in renal function6 and increasing prevalence to around 21–40% in the dialysis population.